# ArteraAI

> ArteraAI is a precision medicine company building multimodal AI tests that personalize cancer therapy. Its flagship ArteraAI Prostate Test is the first AI-enabled predictive and prognostic biomarker recommended in the NCCN Guidelines for localized prostate cancer, validated across five Phase 3 trials.

- **Founded:** 2021
- **Headquarters:** Los Altos, California, United States
- **Founders:** Andre Esteva (Co-founder & CEO), Felix Y. Feng (Co-founder & Chief Medical Officer (UCSF))
- **Team size:** ~140
- **Products:** ArteraAI Prostate Test (Biopsy), ArteraAI Prostate Test (Post-Radical Prostatectomy), Active Surveillance Module
- **Notable:** First AI-enabled predictive and prognostic test included in NCCN Guidelines for prostate cancer (Level IB, Category 2A)., FDA Breakthrough Device Designation and De Novo authorization for the ArteraAI Prostate Test., Validated across five randomized Phase 3 trials.

## Products & services

- **ArteraAI Prostate Test (Biopsy)** — Multimodal AI test that predicts therapy benefit and long-term outcomes from a digitized biopsy slide plus clinical data. FDA De Novo authorized.
- **ArteraAI Prostate Test (Post-Radical Prostatectomy)** — Estimates risk of biochemical recurrence after surgery to guide adjuvant therapy decisions.
- **Active Surveillance Module** — Expansion of the Prostate Test to support active-surveillance candidacy decisions.

## Achievements

- First AI-enabled predictive and prognostic test included in NCCN Guidelines for prostate cancer (Level IB, Category 2A).
- FDA Breakthrough Device Designation and De Novo authorization for the ArteraAI Prostate Test.
- Validated across five randomized Phase 3 trials.
- Raised $175M+ total funding.
- Built on one of the most race-diverse training cohorts in prostate-cancer AI.

## Latest updates

- **2025-12** — Closed an additional ~$65M venture round.
- **2024-02** — Secured $20M to expand the multimodal platform.
- **2024-03** — NCCN Guidelines inclusion for the ArteraAI Prostate Test.
- **2023-03** — Public launch with $90M in initial funding.

## Links

- Website: https://artera.ai
- LinkedIn: https://www.linkedin.com/company/arteraai
- Twitter/X: https://twitter.com/arteraAI

---

Profile page: https://yespress.io/arteraai
Published by YesPress — https://yespress.io
Last updated: 2026-05-19